secwatch.observer — SEC 8-K summary
======================================

Issuer:     aTYR PHARMA INC (ATYR)
CIK:        0001339970
Form:       8-K
Filed at:   2024-05-02T23:59:59+00:00
Accession:  0000950170-24-052058
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

aTyr Pharma Q1 2024 update: Phase 3 EFZO-FIT completes enrollment expected in Q2 2024
--------------------------------------------------------------------------------

- Cash, cash equivalents, restricted cash and investments totaled $87.7 million as of March 31, 2024.
- Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis enrollment completion expected in Q2 2024.
- Phase 2 EFZO-CONNECT study in systemic sclerosis-associated ILD enrolling at multiple U.S. sites.
- R&D expenses of $13.4 million and G&A expenses of $3.5 million for Q1 2024.
- Collaboration revenue of $0.2 million from Kyorin agreement for drug product material sold.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1339970/000095017024052058/0000950170-24-052058-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1339970/000095017024052058/life-20240502.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-052058

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer